Bactrim Dosage and Administration

Standard Treatment Dosing

The American Academy of Pediatrics recommends administering Bactrim at 8-12 mg/kg/day of the trimethoprim component and 40-60 mg/kg/day of sulfamethoxazole, divided into 2 doses given every 12 hours, for most infections in children over 2 months of age 1

Indication-Specific Dosing

For severe MRSA osteomyelitis, the Taiwanese guidelines recommend 4 mg/kg/dose of trimethoprim every 8-12 hours, typically combined with rifampin for >6 weeks 2, 3

Pharmacokinetic Considerations

The standard 8/40 mg/kg/day divided every 12 hours matches adult exposure and achieves therapeutic targets for bacteria with MIC ≤0.5 mg/L in >90% of children, according to the Praxis Medical Insights 1

Monitoring Requirements

Obtain complete blood count with differential and platelet count at treatment initiation, and repeat monthly during prolonged therapy to assess for hematologic toxicity, as recommended by Praxis Medical Insights 4

Important Safety Considerations

The American College of Clinical Pharmacy recommends using Bactrim with caution in patients with G6PD deficiency, renal insufficiency, and hepatic insufficiency, due to the risk of hemolytic anemia, and requires dose adjustment 1
The use of Bactrim may increase the toxicity of methotrexate, enhance the anticoagulant effect of warfarin and other anticoagulants, and increase the hypoglycemia risk of oral hypoglycemics, as reported by Praxis Medical Insights 1

Formulation Considerations

The American Academy of Pediatrics recommends using the liquid formulation of Bactrim for accurate dosing in younger children, particularly those weighing <16 kg, as stated by Praxis Medical Insights 4

Bactrim Dosing Guidelines for Pediatric Patients

Indication-Specific Dosing

For mild-to-moderate infections, such as urinary tract infections or skin and soft tissue infections, in a 50 kg pediatric patient, the American Academy of Pediatrics recommends using 8-10 mg/kg/day of the trimethoprim component, divided every 12 hours, according to the Infectious Diseases Society of America 5
For serious infections, such as severe MRSA, in a 50 kg pediatric patient, the Infectious Diseases Society of America recommends using 10-12 mg/kg/day of the trimethoprim component, or up to 15-20 mg/kg/day divided every 6-8 hours for life-threatening infections 5

Dosing Considerations

The standard 8-12 mg/kg/day dosing achieves therapeutic targets for bacteria with MIC ≤0.5 mg/L in >90% of children is not directly cited, however, the dosing for serious infections is supported by the Infectious Diseases Society of America 5

Dosing Considerations for Trimethoprim-Sulfamethoxazole in Pediatric Patients

Renal Impairment Adjustments

For patients with creatinine clearance 15-30 mL/min, the dose of trimethoprim-sulfamethoxazole should be reduced by 50% to prevent toxicity, as recommended by the Clinical Infectious Diseases guideline 6
For patients with creatinine clearance <15 mL/min, the dose of trimethoprim-sulfamethoxazole should be reduced by 50% or an alternative agent should be used, according to the Clinical Infectious Diseases guideline 6
For treatment dosing with CrCl 10-50 mL/min, the American Academy of Pediatrics recommends administering 3-5 mg/kg every 12 hours (instead of every 6-8 hours) 6
For treatment dosing with CrCl <10 mL/min, the American Academy of Pediatrics suggests administering 3-5 mg/kg every 24 hours 6
Ensuring adequate hydration (at least 1.5 liters daily) is crucial to prevent crystalluria, as stated in the Clinical Infectious Diseases guideline 6

Important Contraindications and Cautions

The use of trimethoprim-sulfamethoxazole should be avoided in patients with severe hepatic impairment, as recommended by the Clinical Infectious Diseases guideline 7

Cotrimoxazole Dosing for Pediatric Patients

Pediatric Dosing Considerations

For non-severe pneumonia, the recommended dose is 8 mg/kg trimethoprim per dose, twice daily, as suggested by The Lancet Infectious Diseases 8
The Centers for Disease Control and Prevention, as reported in MMWR Recommendations and Reports, recommends prophylaxis with 150 mg/m²/day trimethoprim with 750 mg/m²/day sulfamethoxazole, divided twice daily, given 3 consecutive days per week, with a maximum of 320 mg trimethoprim/1600 mg sulfamethoxazole daily 9
For achieving 8 mg/kg trimethoprim per dose every 12 hours, the Centers for Disease Control and Prevention, as reported in MMWR Recommendations and Reports, provides a weight-based dosing table, including:
Weight Dose
10 kg (22 lbs) 1 single-strength tablet (80 mg TMP/400 mg SMX)
20 kg (44 lbs) 1 single-strength tablet
30 kg (66 lbs) 1½ single-strength tablets
Bactrim Dosing Guidelines
Indication-Specific Dosing
For MRSA skin and soft tissue infections, the Infectious Diseases Society of America recommends using the higher end of dosing (2 DS tablets twice daily) for 7-10 days 10
The American Academy of Pediatrics and the Infectious Diseases Society of America suggest that for severe MRSA infections, a dose of 2 double-strength tablets (320 mg TMP/1600 mg SMX) every 12 hours is appropriate, as recommended by the Clinical Infectious Diseases journal 10

Weight	Dose
10 kg (22 lbs)	1 single-strength tablet (80 mg TMP/400 mg SMX)
20 kg (44 lbs)	1 single-strength tablet
30 kg (66 lbs)	1½ single-strength tablets

Important Contraindications and Precautions

The Centers for Disease Control and Prevention and the Clinical Infectious Diseases journal recommend screening for G6PD deficiency before initiating therapy due to hemolytic anemia risk 10

Evidence‑Based Trimethoprim‑Sulfamethoxazole (Bactrim) Dosing Recommendations

Severe MRSA Infections

MRSA meningitis, brain abscess, and other CNS infections – Administer trimethoprim 5 mg/kg per dose every 8–12 hours (dose based on the trimethoprim component). This regimen is supported by clinical data from Clinical Infectious Diseases (2011) and the Journal of Microbiology, Immunology and Infection (2013). [11][12]
MRSA osteomyelitis – Use trimethoprim 3.5–4.0 mg/kg per dose every 8–12 hours, usually combined with rifampin and continued for more than 6 weeks. Evidence drawn from the same two sources as above. [11][12]

Prophylaxis Schedules

Alternative PCP prophylaxis – One double‑strength tablet (160 mg TMP/800 mg SMX) given three times weekly on consecutive days provides effective prophylaxis. Supported by a 2005 Clinical Infectious Diseases guideline. 13
Pediatric PCP prophylaxis (HIV‑exposed/infected children) – Administer 150 mg/m²/day trimethoprim with 750 mg/m²/day sulfamethoxazole, divided twice daily, for three consecutive days each week (maximum 320 mg TMP/1600 mg SMX daily). Recommendation from the 2009 MMWR report. 14

Renal Impairment Dose Adjustments

Prophylaxis in patients with creatinine clearance (CrCl) 15–30 mL/min – Reduce the standard dose by 50% (i.e., give half of the usual dose). 13
Prophylaxis in patients with CrCl < 15 mL/min – Reduce the dose by 50% or consider an alternative agent. 13
PCP treatment when CrCl 10–50 mL/min – Give trimethoprim 3–5 mg/kg every 12 hours (instead of every 6–8 hours). 13
PCP treatment when CrCl < 10 mL/min – Give trimethoprim 3–5 mg/kg once daily (every 24 hours). 13
FDA‑label renal dosing – For CrCl 15–30 mL/min, use half the usual regimen; for CrCl < 15 mL/min the standard label advises against use, though clinical guidance endorses a reduced dose. 13

Monitoring and Supportive Care

Renal function monitoring – During high‑dose therapy, regularly assess creatinine clearance and electrolytes to detect accumulation and toxicity. Evidence from the 2005 Clinical Infectious Diseases guideline. 13
Hydration – Ensure patients ingest at least 1.5 L of fluid daily to prevent crystalluria, especially when receiving high‑dose trimethoprim‑sulfamethoxazole. Supported by the same 2005 guideline. 13
Risk of toxicity with inadequate renal dose reduction – Failure to adjust dosing for CrCl < 30 mL/min markedly increases the risk of adverse effects. 13
Crystalluria risk with insufficient hydration – Inadequate fluid intake heightens the likelihood of crystal formation in the urinary tract during high‑dose therapy. 13

Bactrim (Trimethoprim‑Sulfamethoxazole) Pediatric Guidelines

Dosing Recommendations

Treatment Duration

Monitoring Requirements

Management of Adverse Reactions

Pediatric Trimethoprim Dosing Calculations

Dose Determination

For a pediatric patient weighing approximately 31 kg, a trimethoprim dose of 10 mg/kg per day provides a total daily dose of about 313 mg, which should be divided into two equal doses of roughly 156 mg each (≈156.5 mg per dose) 18.

Suspension Concentration

The liquid formulation is supplied as a suspension containing 40 mg of trimethoprim per 5 mL of fluid 18.

Pneumocystis Jiroveci Pneumonia (PCP) Management with Bactrim

Dosing and Treatment Regimens

Therapeutic dosing for PCP – The CDC recommends trimethoprim 15–20 mg/kg/day (equivalent to sulfamethoxazole 75–100 mg/kg/day) divided every 6 hours for a total of 14–21 days in pediatric patients with PCP. 19
Transition to oral therapy – After resolution of acute pneumonitis, patients may be switched to an oral formulation using the same total daily dose, provided there is no malabsorption or diarrhea. 19

Adverse‑Reaction Management

Mild rash – For a mild cutaneous rash, temporarily discontinue Bactrim and restart the medication once the rash has resolved. 19
Severe, life‑threatening reactions – Permanently discontinue Bactrim for Stevens‑Johnson syndrome, urticarial rash, anaphylaxis, or severe hypotension, and do not rechallenge the patient. 19

Frequency and Severity of Adverse Events

Common adverse effects – Rash, pruritus, nausea, leukopenia, and transaminase elevation occur frequently with Bactrim but are rarely life‑threatening. 20
Age‑related reaction rates – The incidence of adverse reactions is lower in children (approximately 15 %) compared with adults. 19

Treatment Duration

PCP treatment course – The recommended duration of therapy for PCP is 14–21 days. 19

Bactrim (Trimethoprim‑Sulfamethoxazole) Evidence‑Based Recommendations

MRSA Skin and Soft‑Tissue Infection Treatment

For purulent cellulitis caused by community‑associated MRSA, prescribe 1–2 double‑strength tablets orally twice daily for 7–10 days; the higher dose (2 tablets twice daily) is recommended for more severe infections. 21

Need for Additional Streptococcal Coverage

Although TMP‑SMX has excellent activity against CA‑MRSA, its activity against β‑hemolytic streptococci is poorly defined; therefore, add β‑lactam coverage when treating non‑purulent cellulitis where streptococcal infection is possible. 21

Complicated Skin and Soft‑Tissue Infection Treatment

For complicated SSTIs (including those with deeper tissue involvement), use 1–2 double‑strength tablets orally or the equivalent IV dose every 12 hours. 21

Comparative Risk of Clostridioides difficile Infection

TMP‑SMX is associated with a lower incidence of C. difficile–associated disease compared with clindamycin. 21

Pregnancy Contraindication (Third Trimester)

Bactrim should be avoided in term pregnancy (third trimester) because of potential fetal risk (category C/D). 21

Prophylaxis Regimens for Adults

Standard prophylaxis: 1 double‑strength tablet daily.
Alternative regimen (supported by evidence): 1 double‑strength tablet administered on three consecutive days each week (e.g., Monday‑Tuesday‑Wednesday). 22

Renal Impairment – Prophylaxis Dose Adjustments

For patients with creatinine clearance (CrCl) 15–30 mL/min, reduce the prophylactic dose by 50% (i.e., half the usual regimen). 22
For CrCl < 15 mL/min, either reduce the dose by 50% or select an alternative agent. 22

Renal Impairment – PCP Treatment Dose Adjustments

When CrCl is 10–30 mL/min, use trimethoprim 5 mg/kg every 12 hours (instead of the usual q6–8 hours). 22
When CrCl is < 10 mL/min, use trimethoprim 5 mg/kg every 24 hours. 22